Catalpa Ventures is a Luxembourg-based venture capital firm founded in 2024 with a dedicated focus on early-stage healthtech in Europe. The firm was created by experienced medical and scientific operators with the goal of backing startups that deliver measurable impact across healthcare systems. Catalpa positions itself as a specialist investor, combining clinical expertise with venture execution to support founders building practical, scalable health technologies.
Catalpa Ventures invests exclusively in healthtech, with a focus on digital health tools, disease prevention technologies, and workflow solutions for clinics, laboratories, and healthcare providers.
The firm prioritizes technologies that improve disease management, support healthcare professionals, and reduce administrative and operational burden across clinical and research environments. Its scope spans care delivery, diagnostics enablement, and data-driven healthcare operations.
Catalpa Ventures is currently raising Catalpa Health Fund I, a €30 million early-stage fund, with €10 million already secured in initial commitments. The fund is backed by a mix of entrepreneurs, family offices, and industry leaders, and is targeting a final close in the first quarter of 2027. Catalpa Health Fund I plans to make 15 to 20 investments over a four-year investment period, with initial ticket sizes ranging from €300,000 to €1.5 million.
The fund is structured to reserve follow-on capital for its highest-performing portfolio companies, allowing Catalpa to support founders beyond the first round. The strategy is firmly Europe-first, backing startups developing technologies that improve prevention, care delivery, and operational efficiency across healthcare systems.
Leadership
Catalpa Ventures was founded by Dr. Thomas Goergen, Prof. Silke R. Sperling, and Dr. Christian Goergen. The founding team brings deep domain expertise across medicine, life sciences, and healthcare operations, combining academic, clinical, and entrepreneurial backgrounds. This foundation shapes a highly hands-on approach to evaluating products, evidence, and real-world adoption.
Investment Strategy
Catalpa Ventures leads or co-leads early-stage rounds, primarily at seed level, and works closely with founders on clinical validation, regulatory positioning, and early market entry. The firm emphasizes impact alongside commercial viability, favoring solutions that can be integrated into existing healthcare workflows. Catalpa supports founders with sector-specific insight, industry connections, and long-term guidance rather than rapid scaling at the expense of product quality or outcomes.
Notable Investments
Catalpa Ventures’ first disclosed investment is Noah Labs, a telemedicine platform focused on heart failure management that uses voice analytics to improve patient monitoring and reduce hospitalizations. The investment reflects Catalpa’s focus on prevention, data-driven care, and solutions designed for real clinical use.
Notable Exits
Catalpa Ventures is an emerging firm and has not yet reported exits.
Other
Catalpa Ventures is a focused healthtech specialist rather than a generalist VC. The firm is particularly well-suited for teams with strong clinical grounding or regulated healthcare products that require thoughtful validation and adoption strategies. Catalpa values impact, evidence, and founder alignment, and is building a concentrated portfolio rather than chasing volume.
Luxembourg
